As of now, the pre-condition for any vaccine to be implemented in India is that you have to do a bridging trial, said Niti Aayog member VK Paul who also heads National Expert Group On Vaccine Administration for COVID-19 (NEGVAC)

The pre-prints or preliminary reports of research work related to Covaxin, which are yet to be peer-reviewed are already posted on pre-print servers like bioRxiv, medRxiv and Research Square

A team from Precisa Medicamentos visited the Bharat Biotech's Hyderabad facility last week to discuss potential export possibilities of Covaxin with Chairman Dr Krishna Ella on the January 7-8

Among these vaccines are those developed by Zydus Cadila, Biological E and Gennova, along with Russia's Sputnik-V vaccine

Several states have made all necessary preparations for the first phase of the exercise comprising identifying vaccination sites and registration of healthcare and other frontline workers

Coronavirus vaccination drive: The letter alleged irregularities and ethical violations in the conduct of the clinical trial of Covaxin by the People's College of Medical Sciences & Research Centre, Bhopal

Bharat Biotech revealed that one of the participants for Phase III trials passed away on December 21, 2020, and the death was reported to the People's College of Medical Sciences and Research Centre by the son of the deceased

Bharat Biotech has sent a proposal to the Drugs Controller General of India (DCGI) to seek its approval for trials of a nasal vaccine against COVID-19. The firm recently introduced Covaxin vaccine in India, which has been approved for emergency use in the country. The trials for nasal vaccine will be conducted on at least 30-45 volunteers above the age of 18 years at four trial sites in the country, including Bhubaneswar, Pune, Nagpur and Hyderabad. Watch the video for more.Also Read: Phase 1 vaccination to cost govt Rs 21,000-27,000 crore: SBI Research

Tesla and SpaceX CEO Elon Musk is now the richest person in the world, according to latest data on Bloomberg Billionaires Index; Union Health Minister Dr Harsh Vardhan on Thursday said that the COVID-19 vaccines 'Covishield' and 'Covaxin' are on the verge of being rolled out; Rishad Premji, Chairman of Wipro, has written a letter to his employees thanking them for their contribution and dedication towards the company. Watch this and more on News Blast.Also Read: Bharat Biotech seeks DCGI nod to conduct trials of nasal Covid-19 vaccine

Bharat Biotech chairman Krishna Ella says this nasal vaccine will revolutionise Indian vaccine making capabilities and help it leapfrog along with Europe, the US and China

Dr Krishna Ella, Chairman of Bharat Biotech, said that unlike the clinical trials of AstraZeneca vaccine (which has been licensed to Serum Institute of India), Bharat Biotech did not try to suppress the side effects of vaccine by giving paracetamol to the volunteers. He also said that for his company safety came first. Watch him in conversation with Rajeev Dubey, Editor, Business Today.Also Read: China denies entry to WHO team investigating COVID-19 origins

The vaccine produced by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology, Pune, has courted many controversies since it began its first human trials. In this video, Bharat Biotech chief Dr Krishna Ella talks to Business Today Editor, Rajeev Dubey, about vaccine efficacy and why people get suspicious about Indian companies.

(For) all our vaccines, we are looking at right now..(we) are targeting 2-8 degree because our logistics are worked out on that basis and we are working on that, DBT secretary Renu Swarup said at a press briefing

Bhopal gas activist Rachna Dhingra through a tweet on Sunday had alleged that poor and vulnerable residents of gas affected communities were herded by the People's University with a promise of Rs 750

Talking to BusinessToday.In, Dr. Krishna Ella, Chairman and MD, Bharat Biotech, said the trial would take around four months and if the regulator gives quick permission the company might start with the clinical trial

There was immense pressure on governments to develop a vaccine at the earliest due to the destruction COVID-19 pandemic was unleashing. This led to a race among pharma companies to be the first to develop a vaccine

COVID-19 vaccine update: India has approved two coronavirus vaccines for emergency use - Bharat Biotech-ICMR's Covaxin and Covishield manufactured by Pune's Serum Institute

Patna airport had given the list of passengers who came from the UK between November 23 and December 31 and their addresses. But when health officials went to their houses to put them under quarantine, they found the people were missing

Without naming Serum Institute CEO Adar Poonawalla, who had termed vaccines other than that of Pfizer, Moderna and Oxford-AstraZeneca as 'just like water', Krishna Ella said, 'We do 200 per cent honest clinical trials and yet we receive backlash'

Krishna Ella, Chairman of Bharat Biotech, said that unlike the clinical trials of AstraZeneca vaccine, Bharat Biotech did not try to supress the side effects of vaccine by giving paracetamol to the volunteers